Astellas DRC Phase 1b, Dose Escalation Evaluation of Safety and Tolerability and a Ph 2, Randomized, Parallel Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to AMD

Administered By

Awarded By

Contributors

Start/End

  • March 30, 2017 - May 14, 2022